Results 341 to 350 of about 399,014 (392)

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children

Clinical Drug Investigation, 2007
By the end of 2006, approximately 2.3 million children worldwide were living with HIV infection, representing about 15% of all HIV-infected individuals but only 5-7% of the total population of treated patients worldwide. Despite a general increase in the use of antiretroviral therapy (ART) in resource-limited settings, appropriate care and ART remain ...
GIAQUINTO, CARLO, RAMPON O, PENAZZATO M, FREGONESE F, DE ROSSI, ANITA, D'ELIA R.   +5 more
openaire   +4 more sources

Animal Lentivirus Replication and Reverse Transcriptase Inhibitors [PDF]

Clinical Infectious Diseases, 1989
We summarize the pathogenesis of animal lentiviruses (visna-maedi virus, caprine arthritis and encephalitis virus, and equine infectious anemia virus), which have raised considerable interest since the discovery of human lentiviruses. The human lentiviruses possess structural, genetic, and clinical properties similar to those of animal lentiviruses. We
J. A. Nicolas, C. Bosgiraud, S. Beaussoleil   +2 more
openaire   +2 more sources

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

AIDS, 2009
The use of nonnucleoside reverse transcriptase inhibitor (NNRTI) + protease inhibitor regimen for the treatment of antiretroviral-naive patients was less successful than classical nucleoside reverse transcriptase inhibitor (NRTI) based regimen and associated with more resistance for protease inhibitors and NNRTIs. The selection for NNRTI resistance was
Claudine Duvivier, Vincent Calvez, Lambert Assoumou, Christine Katlama, Cathia Soulié, Jean-Michel Molina, Zaina Ait-Arkoub, Anne-Geneviève Marcelin, Gilles Peytavin, Dominique Costagliola, Jade Ghosn   +10 more
openaire   +3 more sources

HIV Inhibitors Targeted at the Reverse Transcriptase

AIDS Research and Human Retroviruses, 1992
HIV inhibitors targeted at the virus-associated reverse transcriptase (RT) can be divided into two groups, depending on whether they are targeted at the substrate or nonsubstrate binding site. To the first group belong the 2',3'-dideoxynucleosides (i.e., DDC, DDI), 3'-azido-2',3'-dideoxynucleosides (i.e., AZT), 3'-fluoro-2',3'-dideoxynucleosides (i.e.,
openaire   +3 more sources

Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase.

Journal of Medicinal Chemistry, 2014
Bisphosphonates can mimic the pyrophosphate leaving group of the nucleotidyl transfer reaction and effectively inhibit RNA/DNA polymerases. In a search of HIV-1 reverse transcriptase (RT) inhibitors, a new chemotype of nonhydrolyzable purine diphosphate ...
Cyrus M Lacbay, J. Mancuso, Yih‐Shyan Lin, Nicholas J Bennett, M. Götte, Y. Tsantrizos   +5 more
semanticscholar   +1 more source

Affinity of reverse transcriptase for some polynucleotide inhibitors

Archives of Biochemistry and Biophysics, 1984
The relative affinity of avian myeloblastosis virus reverse transcriptase for (U)n and a series of (U)n analogs has been measured directly in solution under conditions previously used to demonstrate the inhibitory properties of these polynucleotides.
Albert M. Bobst, P.E. Warwick-Koochaki
openaire   +3 more sources

Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.

Journal of Medicinal Chemistry, 2013
Novel 6-substituted-4-cycloalkyloxy-pyridin-2(1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), and their biological activity was evaluated.
Amin Li, Yabo Ouyang, Ziyun Wang, Yuanyuan Cao, Xiangyi Liu, Liqiong Ran, Chao Li, Li Li, Liang Zhang, Kang Qiao, Weisi Xu, Y. Huang, Zhili Zhang, Chao Tian, Zhenming Liu, Shibo Jiang, Y. Shao, Yansheng Du, Liying Ma, Xiaowei Wang, Junyi Liu   +20 more
semanticscholar   +1 more source

Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors

Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 1995
The majority of antiretroviral agents used in the treatment of HIV are targeted at the HIV reverse transcriptase (RT) enzyme. In a continuing effort to develop more effective antiviral regimens, drugs that target other specific enzymes in the virus replication cycle are under development. A promising new class of drugs is the protease inhibitors. These
openaire   +3 more sources

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

2013
HIV is a retrovirus; the retroviral life cycle is characterized by two specific steps: (1) the conversion of the single-stranded RNA genome found in the virion into double-stranded DNA by the viral enzyme reverse transcriptase (RT) and (2) the subsequent insertion of this DNA copy into the host genome by the viral enzyme integrase.
Stephen H. Hughes, Kalyan Das, Eddy Arnold   +2 more
openaire   +2 more sources

Quinolinehydrazones as inhibitors of retroviral reverse transcriptase.

Farmaco (Societa chimica italiana : 1989), 1992
The inhibitory activity of a series of 2- and 4-quinolinehydrazones on retroviral reverse transcriptase has been studied on enzymes from M-MuLV, RAV-2, and on a crude lysate of HIV-1, assuming the first two enzymes as potential models of the third. The highest activity is mainly found in lipophilic, water soluble 4-quinolinehydrazones.
C. Bartolucci, L. Cellai, DI FILIPPO, PATRIZIA, V. Brizzi, C. Pellerano, L. Savini, A. Benedetto, G. Elia   +7 more
openaire   +2 more sources